Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXNX NASDAQ:CSII NASDAQ:INO NASDAQ:LUNG NASDAQ:SILK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXNXAxonics$70.98$70.61$67.49▼$71.05$3.63B0.82429,979 shsN/ACSIICardiovascular Systems$20.00$19.98$12.26▼$20.57$843.96M0.74765,906 shs4,300 shsINOInovio Pharmaceuticals$1.38-1.1%$1.95$1.30▼$12.33$50.06M1.31807,000 shs1.02 million shsLUNGPulmonx$2.64-0.5%$3.07$2.50▼$9.37$106.29M0.45305,012 shs75,171 shsSILKSilk Road Medical$27.49$27.31$6.08▼$27.51$1.12B1.531.20 million shsN/A7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXNXAxonics0.00%0.00%0.00%0.00%+4.81%CSIICardiovascular Systems0.00%0.00%0.00%0.00%0.00%INOInovio Pharmaceuticals-4.14%-3.14%-38.22%-13.66%-85.02%LUNGPulmonx-2.93%-4.50%-22.06%-49.52%-58.27%SILKSilk Road Medical0.00%0.00%0.00%0.00%+1.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXNXAxonicsN/AN/AN/AN/AN/AN/AN/AN/ACSIICardiovascular SystemsN/AN/AN/AN/AN/AN/AN/AN/AINOInovio Pharmaceuticals3.91 of 5 stars3.31.00.04.42.90.01.3LUNGPulmonx3.1897 of 5 stars3.33.00.00.02.53.30.6SILKSilk Road Medical0.5722 of 5 stars1.00.00.04.30.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXNXAxonics 2.00HoldN/AN/ACSIICardiovascular Systems 0.00N/AN/AN/AINOInovio Pharmaceuticals 2.60Moderate Buy$8.80540.00% UpsideLUNGPulmonx 2.63Moderate Buy$11.53336.88% UpsideSILKSilk Road Medical 2.00Hold$27.500.04% UpsideCurrent Analyst Ratings BreakdownLatest SILK, LUNG, AXNX, CSII, and INO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025INOInovio PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$5.005/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/14/2025INOInovio PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.005/14/2025INOInovio PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $13.005/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXNXAxonics$366.38M9.90$0.13 per share561.96$12.59 per share5.64CSIICardiovascular Systems$239.84M3.52N/AN/A$6.12 per share3.27INOInovio Pharmaceuticals$283.10K178.12N/AN/A$1.90 per share0.72LUNGPulmonx$83.79M1.27N/AN/A$2.17 per share1.22SILKSilk Road Medical$177.13M6.31N/AN/A$3.88 per share7.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXNXAxonics-$6.09M-$0.12N/A80.66N/A-1.31%0.36%0.31%N/ACSIICardiovascular Systems-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/AINOInovio Pharmaceuticals-$107.25M-$3.19N/AN/AN/AN/A-136.93%-89.99%8/6/2025 (Estimated)LUNGPulmonx-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)SILKSilk Road Medical-$55.74M-$1.37N/AN/AN/A-29.53%-37.30%-21.57%N/ALatest SILK, LUNG, AXNX, CSII, and INO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025LUNGPulmonx-$0.40N/AN/AN/A$23.46 millionN/A5/13/2025Q1 2025INOInovio Pharmaceuticals-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXNXAxonicsN/AN/AN/AN/AN/ACSIICardiovascular SystemsN/AN/AN/AN/AN/AINOInovio PharmaceuticalsN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/ASILKSilk Road MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXNXAxonicsN/A8.166.40CSIICardiovascular Systems0.086.044.92INOInovio PharmaceuticalsN/A2.632.63LUNGPulmonx0.384.974.29SILKSilk Road Medical0.497.636.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXNXAxonics99.48%CSIICardiovascular Systems86.61%INOInovio Pharmaceuticals26.79%LUNGPulmonx91.04%SILKSilk Road MedicalN/AInsider OwnershipCompanyInsider OwnershipAXNXAxonics1.85%CSIICardiovascular Systems3.80%INOInovio Pharmaceuticals2.30%LUNGPulmonx6.80%SILKSilk Road Medical3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXNXAxonics61051.11 million50.16 millionOptionableCSIICardiovascular Systems78042.20 million40.59 millionOptionableINOInovio Pharmaceuticals32036.67 million35.83 millionOptionableLUNGPulmonx25040.26 million37.52 millionOptionableSILKSilk Road Medical41040.63 million37.91 millionOptionableSILK, LUNG, AXNX, CSII, and INO HeadlinesRecent News About These CompaniesPhotos show where US and China have sent hospital shipsJune 18, 2025 | msn.comThree Andritz spunlace lines for Alear Silk RoadApril 25, 2025 | innovationintextiles.comIANDRITZ To Supply Three Spunlace Lines To Alear Silk Road New Materials, ChinaApril 25, 2025 | textileworld.comT2,200-year-old grave in China contains 'Red Princess of the Silk Road' whose teeth were painted with a toxic substanceMarch 12, 2025 | msn.comXinjiang a front-runner in BRI medical cooperationMarch 7, 2025 | chinadaily.com.cnCEndologix Appoints Andrew Davis as Chief Commercial OfficerMarch 3, 2025 | businesswire.comChina’s Belt and Road Initiative: The art of exploiting threats and opportunitiesFebruary 21, 2025 | tehrantimes.comTBoston Scientific ramped up headcount, real estate footprint in 2024February 21, 2025 | bizjournals.comTrump pardons Silk Road founder Ross Ulbricht for online drug schemeJanuary 23, 2025 | reuters.comTrump pardons Ross Ulbricht, creator of online black market for illegal drugsJanuary 23, 2025 | msn.comTrump pardons founder of Silk Road websiteJanuary 23, 2025 | msn.comSilk Road founder Ross Ulbricht went to prison a libertarian hero. Trump just set him free.January 22, 2025 | msn.comTrump pardons online drug marketplace Silk Road founder, Austin native Ross UlbrichtJanuary 22, 2025 | msn.comWho Is Ross Ulbricht? What To Know About ‘Silk Road’ Drug Marketplace Founder Pardoned By Trump.January 22, 2025 | msn.comTrump pardons Ross Ulbricht, founder of online drug market Silk RoadJanuary 22, 2025 | msn.comTrump Pardons Creator of Silk Road Drug MarketplaceJanuary 22, 2025 | nytimes.comChinese, Pakistani firms sign $250m MoUsJanuary 19, 2025 | tribune.com.pkTMoUs worth $250m signed with Chinese medical companiesJanuary 19, 2025 | dawn.comDPakistani, Chinese companies ink $250mn MoUs to boost medical sectorJanuary 18, 2025 | brecorder.comBPakistani, Chinese companies ink $250 million MoUs to boost medical sectorJanuary 18, 2025 | business-standard.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseSouthwest Airlines: Short Interest Plunges—Should You Buy?By Gabriel Osorio-Mazilli | June 17, 2025View Southwest Airlines: Short Interest Plunges—Should You Buy?SILK, LUNG, AXNX, CSII, and INO Company DescriptionsAxonics NASDAQ:AXNXAxonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Cardiovascular Systems NASDAQ:CSIICardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.Inovio Pharmaceuticals NASDAQ:INO$1.38 -0.02 (-1.08%) As of 12:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.Pulmonx NASDAQ:LUNG$2.64 -0.01 (-0.45%) As of 12:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Silk Road Medical NASDAQ:SILKSilk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
